Shandong Sito Bio-technology Co Ltd (300583) - Total Liabilities
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has total liabilities worth CN¥1.06 Billion CNY (≈ $155.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shandong Sito Bio-technology Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300583 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Shandong Sito Bio-technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fortune Ng Fung Food Hebei Co Ltd
SHG:600965
|
China | CN¥462.39 Million |
|
Firm Capital Mortgage Invest Corp
TO:FC
|
Canada | CA$133.58 Million |
|
Materialise NV
NASDAQ:MTLS
|
USA | $162.93 Million |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
China | CN¥354.76 Million |
|
Peijia Medical Limited
F:4WO
|
Germany | €798.71 Million |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
USA | $72.73 Million |
|
Citizens Financial Services Inc. Common Stock
NASDAQ:CZFS
|
USA | $2.68 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Shandong Sito Bio-technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Shandong Sito Bio-technology Co Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Sito Bio-technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shandong Sito Bio-technology Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.14 Billion ≈ $167.06 Million |
-2.82% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
-4.04% |
| 2022-12-31 | CN¥1.22 Billion ≈ $179.15 Million |
-1.09% |
| 2021-12-31 | CN¥1.24 Billion ≈ $181.11 Million |
+7.63% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.27 Million |
+4.49% |
| 2019-12-31 | CN¥1.10 Billion ≈ $161.04 Million |
+50.21% |
| 2018-12-31 | CN¥732.63 Million ≈ $107.21 Million |
+130.81% |
| 2017-12-31 | CN¥317.42 Million ≈ $46.45 Million |
-4.74% |
| 2016-12-31 | CN¥333.22 Million ≈ $48.76 Million |
+0.48% |
| 2015-12-31 | CN¥331.62 Million ≈ $48.53 Million |
+53.30% |
| 2014-12-31 | CN¥216.31 Million ≈ $31.65 Million |
+93.44% |
| 2013-12-31 | CN¥111.83 Million ≈ $16.36 Million |
+306.45% |
| 2012-12-31 | CN¥27.51 Million ≈ $4.03 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more